Antiviral therapy of COVID-19

Antiviral therapy of COVID-19

The COVID-19 pandemic required rapid response to the needs of critically ill patients, and one of the solutions was re-purposing of drugs with wide spectrum of antiviral action for treatment of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection. The re-purposing characteristi...

Full description

Bibliographic Details
Main Author:	Janković Slobodan M.
Format:	Article
Language:	English
Published:	Medical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of Medicine 2020-01-01
Series:	Scripta Medica
Subjects:	covid-19 antiviral agents drug repurposing out-of-label use adverse effects
Online Access:	https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2020/2490-33292003131J.pdf

Similar Items

Repurposed antimicrobial and antiviral drugs for COVID-19 treatment: safety and side effects in real clinical practice (scientific review)
by: Marina V. Leonova
Published: (2022-09-01)

Off-Label Drug Use Medication Guidelines of Immunotherapy Drugs and COVID-19 Antiviral Drugs for COVID-19 in Vulnerable Populations
by: Li Ye, Liu Xingling, Pan Yunqi, Lin Yanduan, Xu Lejia, Zheng Danwei, Jiang Caiyun, Yang Qi, Mai Haiyan
Published: (2023-02-01)

RETRACTED: <em>Artemisia</em> Extracts and Artemisinin-Based Antimalarials for COVID-19 Management: Could These Be Effective Antivirals for COVID-19 Treatment?
by: Pawan K. Agrawal, et al.
Published: (2022-06-01)

COVID-19: How Effective Are the Repurposed Drugs and Novel Agents in Treating the Infection?
by: Chow Suet-May, et al.
Published: (2022-12-01)

Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy
by: Tonino Alonzi, et al.
Published: (2021-12-01)

Overview of Antiviral Drug Therapy for COVID-19: Where Do We Stand?
by: Renata Esposito, et al.
Published: (2022-11-01)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
by: Ashley Jia Wen Yip, et al.
Published: (2022-06-01)

Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery
by: Abdulaziz L, et al.
Published: (2022-03-01)

Decoding information on COVID–19: Ontological approach towards design possible therapeutics
by: Swaminathan K. Jayachandran, et al.
Published: (2021-01-01)

Amphotericin B as antiviral drug: Possible efficacy against COVID-19
by: Falah Hasan Obayes AL-Khikani
Published: (2020-01-01)

Antiviral Screening of Multiple Compounds against Ebola Virus
by: Stuart D. Dowall, et al.
Published: (2016-10-01)

Valinomycin as a potential antiviral agent against coronaviruses: A review
by: Dong Zhang, et al.
Published: (2020-10-01)

β-Cyclodextrins as affordable antivirals to treat coronavirus infection
by: Dalia Raïch-Regué, et al.
Published: (2023-08-01)

Tamoxifen from chemotherapy to antiviral drug: Possible activity against COVID-19
by: Huda Ali Salman Almosawey, et al.
Published: (2020-01-01)

An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?
by: Omkar Indari, et al.
Published: (2021-03-01)

Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till Viral Clearance: A Retrospective Cohort Study
by: Wael Hafez, et al.
Published: (2022-04-01)

Recent progress on drugs discovery study for treatment of COVID-19: repurposing existing drugs and current natural bioactive molecules
by: Ika Oktavianawati, et al.
Published: (2023-12-01)

Effects of antivirals on patients with COVID-19 breakthrough
by: Hong Tham Pham, et al.
Published: (2024-01-01)

Drug Repurposing Approach against Novel Coronavirus Disease (COVID-19) through Virtual Screening Targeting SARS-CoV-2 Main Protease
by: Kamrul Hasan Chowdhury, et al.
Published: (2020-12-01)

COVID-19: Ivermectin; Molecular Mechanisms, Limitations, Suggestions
by: Mustafa KESMEN, et al.
Published: (2020-12-01)

Drug-drug interactions with direct-acting antivirals — less is more
by: Grace Lai-Hung Wong
Published: (2021-01-01)

Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial
by: Laurens Liesenborghs, M.D., et al.
Published: (2021-04-01)

The Potential of Antiviral Peptides as COVID-19 Therapeutics
by: Arun Suria Karnan Mahendran, et al.
Published: (2020-09-01)

FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2
by: Ahmed Mostafa, et al.
Published: (2020-12-01)

An Overview of Repurposed Drugs for Potential COVID-19 Treatment
by: Kamini Govender, et al.
Published: (2022-11-01)

Antiviral Potential of Azelastine against Major Respiratory Viruses
by: Katrin Fischhuber, et al.
Published: (2023-11-01)

Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs
by: Emily L.C. Tan, et al.
Published: (2004-04-01)

Safety and Efficacy of Antiviral Drugs for the Treatment of COVID-19: A Systematic Review
by: Nie Z, et al.
Published: (2022-08-01)

Experience of a Portuguese Center: Effectiveness of Direct-Acting Antiviral Therapy for Hepatitis C
by: Fátima Falcão, et al.
Published: (2019-03-01)

Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data
by: Fadhl M. Alakwaa
Published: (2020-04-01)

Dexamethasone Treatment for Covid-19, a Curious Precedent Highlighting a Regulatory Gap
by: Lucia Gozzo, et al.
Published: (2020-11-01)

Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: an estimate
by: Alexiane PRADELLE, et al.
Published: (2024-02-01)

A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives
by: Abas Sezer, et al.
Published: (2022-05-01)

DRaW: prediction of COVID-19 antivirals by deep learning—an objection on using matrix factorization
by: S. Morteza Hashemi, et al.
Published: (2023-02-01)

Editorial: Drug Repurposing for COVID-19 Therapy
by: Rafael Maldonado, et al.
Published: (2021-08-01)

Drug Repurposing of the Antiviral Drug Acyclovir: New Pharmaceutical Salts
by: Paulo Nunes, et al.
Published: (2023-05-01)

Antiviral drug discovery for emerging diseases and bioterrorism threats /
by: Torrence, Paul F.
Published: (2005)

The Regulatory Challenges for Drug Repurposing During the Covid-19 Pandemic: The Italian Experience
by: Lucia Gozzo, et al.
Published: (2020-09-01)

L1000 connectivity map interrogation identifies candidate drugs for repurposing as SARS-CoV-2 antiviral therapies
by: Wezi Sendama
Published: (2020-01-01)

A Novel Oral Antiviral Drug for Covid-19. Can It Make a Difference?
by: Moizza Tahir
Published: (2023-03-01)